Literature DB >> 15257098

The extracellular matrix differentially regulates the expression of PTHrP and the PTH/PTHrP receptor in FG pancreatic cancer cells.

John J Grzesiak1, Paul Clopton, Cheryl Chalberg, Kathy Smith, Douglas W Burton, Steve Silletti, A R Moossa, Leonard J Deftos, Michael Bouvet.   

Abstract

OBJECTIVES: Previous studies by our laboratory have demonstrated that parathyroid hormone-related protein (PTHrP) and its receptor (PTH/PTHrP receptor) are commonly expressed in pancreatic cancer and suggest their participation in the progression of this devastating disease. It has also been demonstrated that one of the major hallmarks of pancreatic adenocarcinoma is an increased production of the extracellular matrix (ECM), a critical regulator of diverse cellular processes such as differentiation, proliferation, and angiogenesis. The present study focused on the relationship between the PTHrP and ECM axes in the pathobiology of pancreatic cancer. METHOD AND
RESULTS: Using the FG pancreatic adenocarcinoma cell line, we demonstrate a significant inverse correlation between FG cell proliferation and PTHrP expression that depended on the ECM protein on which the cells were cultured (P < 0.05). Generally, ECM proteins that promoted the strongest proliferation, including type I collagen, type IV collagen, and laminin, resulted in decreased expression of PTHrP. Conversely, ECM proteins that promoted the weakest proliferation, including fibronectin, vitronectin, and BSA, resulted in increased expression of PTHrP. A similar trend was found between FG cell proliferation and the PTH/PTHrP receptor expression, with Pearson correlation coefficients of 0.480 (mRNA) and -0.591 (protein).
CONCLUSION: These observations demonstrate a unique functional relationship between the ECM and PTHrP axes and have important implications for our understanding of the complex mechanisms responsible for the progression of pancreatic cancer and its metastases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257098     DOI: 10.1097/00006676-200408000-00001

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Knockdown of the β(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis.

Authors:  John J Grzesiak; Hop S Tran Cao; Douglas W Burton; Sharmeela Kaushal; Fabian Vargas; Paul Clopton; Cynthia S Snyder; Leonard J Deftos; Robert M Hoffman; Michael Bouvet
Journal:  Int J Cancer       Date:  2011-04-13       Impact factor: 7.396

2.  Type I collagen and divalent cation shifts disrupt cell-cell adhesion, increase migration, and decrease PTHrP, IL-6, and IL-8 expression in pancreatic cancer cells.

Authors:  John J Grzesiak; Kathy C Smith; Cheryl Chalberg; Douglas W Burton; Leonard J Deftos; Michael Bouvet
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 3.  Extracellular Matrix Scaffold Technology for Bioartificial Pancreas Engineering: State of the Art and Future Challenges.

Authors:  Marcus Salvatori; Ravi Katari; Timil Patel; Andrea Peloso; Jon Mugweru; Kofi Owusu; Giuseppe Orlando
Journal:  J Diabetes Sci Technol       Date:  2014-01-01

4.  Divalent cations modulate alpha2beta1 integrin-mediated malignancy in a novel 3-dimensional in vitro model of pancreatic cancer.

Authors:  John J Grzesiak; Fabian Vargas; Michael Bouvet
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

5.  Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells.

Authors:  John J Grzesiak; Kathy C Smith; Douglas W Burton; Leonard J Deftos; Michael Bouvet
Journal:  Surgery       Date:  2007-05-04       Impact factor: 3.982

6.  The alpha2beta1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines.

Authors:  J J Grzesiak; M Bouvet
Journal:  Br J Cancer       Date:  2006-05-08       Impact factor: 7.640

7.  Meta-analysis of several gene lists for distinct types of cancer: a simple way to reveal common prognostic markers.

Authors:  Xinan Yang; Xiao Sun
Journal:  BMC Bioinformatics       Date:  2007-04-06       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.